GSK’s RSV Vaccine Wins Backing From FDA Advisory Panel (1)

GSK Plc’s vaccine for respiratory syncytial virus won the support of a key panel of US regulatory advisers for use in people aged 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV.

The panel of 12 outside advisers to the Food and Drug Administration voted unanimously on Wednesday that GSK’s data show the Arexvy vaccine is effective. The same committee voted 10-2 that company data show the shot is safe. By contrast, it had voted 7-4 with one abstention to recommend Pfizer’s vaccine as both safe and effective in ...